* Celgene Corp., of Warren, N.J., raised $12 million in aprivate placement of convertible debentures. Thecompany's lead compound, Synovir, whose generic nameis thalidomide, is for HIV, cachexia associated withAIDS, cancer and rheumatoid arthritis.
* CellPro Inc., of Seattle, said a federal district court juryin Delaware has decided that the company's Ceprate SCStem Cell Concentration System and its Ceprate LCLaboratory Cell Separation System do not infringepatents held by Johns Hopkins University, of Baltimore,and licensed to Becton Dickinson and Co., of FranklinLakes, N.J., and Baxter Healthcare Corp., of Deerfield,Ill.
* Cephalon Inc., of West Chester, Pa., raised about $10million more than previously reported in its publicoffering in early August through the underwriters'exercise of options for 450,000 shares to cover overallotments. The company sold a total of 3,988,310 sharesfor more than $89 million and net proceeds of $84.4million. (See BioWorld Today, Aug. 2, 1995, p. 1.)
* Interferon Sciences Inc., whose stock was delisted fromthe NASDAQ National Market System, is trading on theNASDAQ Small Cap Market under the same symbol(IFSC). The company also said it registered with theSecurities and Exchange Commission for a publicoffering of between 6.5 million shares and 12 millionshares.
* Vaxcel Inc., a subsidiary of Atlanta-based CytRx Corp.,signed an agreement giving Connaught Laboratories Inc.,of Swiftwater, Pa., an option to develop Vaxel's OptivaxSystem for use with a Connaught vaccine for infectiousdiseases. Optivax is a delivery system designed toimprove the effectiveness of vaccines. No financial termswere announced, but Vaxcel will receive a payment forthe option.
(c) 1997 American Health Consultants. All rights reserved.